Unlock instant, AI-driven research and patent intelligence for your innovation.

Use of fibrates for the preparation of a medicament useful in the treatment of congestive heart failure

A technology for heart failure and fibrates, applied in drug combinations, pharmaceutical formulations, organic active ingredients, etc., can solve problems such as difficult to determine the cause or effect of the disease

Inactive Publication Date: 2006-07-05
SIGMA TAU IND FARMACEUTICHE RIUNITE SPA
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although multiple biochemical, electrophysiological, and functional abnormalities have been identified, it is difficult to determine whether these abnormalities constitute a cause or a consequence of the disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0018] Materials and methods

[0019] Use male Wistar rats weighing 100-120 g, 5 per cage, at a temperature of 21 ± 1 °C and a humidity of 50 ± 15% with a 12 / 12 hour light / dark cycle and 15-20 air changes / hour (cage size: 425mm×266mm×180mm, including sawdust). Animals were fed ad libitum with LP ALTROMIN (REIPER) feed and spring water.

[0020] induction of cardiac hypertrophy

[0021] In rats anesthetized with sodium pentobarbital, left ventricular hypertrophy was induced by narrowing the abdominal aorta with a clip (φ0.8mm) placed in the abdominal aorta between the diaphragm and renal branches; A control group of animals underwent the same surgery, but without narrowing of the aorta (sham operation).

[0022] This randomizes the animals into the following groups:

[0023] Sham group: Operated but not narrowed aorta (n=8)

[0024] Control: Operated and narrowed aorta (n=8)

[0025] CLO: Operated and narrowed aorta and treated with clofibrate 0.2% (60-100 mg / kg / day) ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The use of fibrates, particularly clofibrate, is described for the preparation of a medicament useful in the treatment of congestive heart failure, and particularly for states of heart failure unrelated to dyslipidaemic conditions.

Description

[0001] The invention described herein relates to medicaments for the treatment of cardiovascular disease, particularly congestive heart failure. Background of the invention [0002] Congestive heart failure (CHF) is an important cause of disability and sudden death (approximately 10% / year) with a high incidence (1-5 cases per 1,000 inhabitants in younger age groups; More than 30 cases per 1,000 inhabitants in patients aged 75). [0003] The physiopathological mechanisms involved in the occurrence, development and progression of CHF are still not fully understood. Although multiple biochemical, electrophysiological, and functional abnormalities have been identified, it has been difficult to determine whether these abnormalities constitute a cause or a consequence of the disease. [0004] CHF is caused by the inability of the heart to pump sufficient blood to meet the metabolic demands of various tissues. This condition is accompanied by significant changes in the systems that...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/216A61K31/195A61K31/192A61P9/04A61K45/00A61K31/00A61K31/22
CPCA61K31/216A61K31/00A61K31/192A61K31/195A61P9/00A61P9/04A61K31/215
Inventor A·阿杜尼
Owner SIGMA TAU IND FARMACEUTICHE RIUNITE SPA